This year the National Psoriasis Foundation (NPF) celebrates 50 years of patient support, advocacy, research funding, education, and outreach to the more than 8 million individuals living with psoriasis and psoriatic arthritis. Originally formed in 1966 as The Psoriasis Society of Oregon, and officially becoming the National Psoriasis Foundation in 1967, its mission is focused on driving efforts to cure psoriatic disease and dramatically improving the lives of those affected.
“NPF has been a pioneer in supporting research efforts that have led to the groundbreaking treatments used today,” said Randy Beranek, NPF president and chief executive officer. “During our 50th year, we are excited to recognize the people and milestones that have contributed so much to the psoriatic disease community, and remain committed to supporting research efforts towards finding a cure and dramatically improving the health outcomes of all affected by psoriasis and psoriatic arthritis.”
Throughout its first 50 years, NPF has made significant contributions in advancing the research of treatments that have helped millions of people. NPF has supported innovative approaches to treating psoriasis and psoriatic arthritis, including topical medications and the biologic treatments that exist today. To date, NPF has funded more than $15 million in research grants and fellowships. To commemorate the 50th anniversary, NPF plans to raise an additional $2 million for early scientific career research programs in 2017.
Much work still needs to be done to improve access to treatments and to find a cure, according the NPF. “We have only scratched the surface of what could be possible in treating—and ultimately curing—psoriasis and psoriatic arthritis. Advancements in psoriatic disease research are happening all the time, and NPF remains committed to funding this research while offering programs and services that support even more patients,” said Colby Evans, MD, NPF board chair.
NPF milestones achievements include securing for line-item funding in a federal budget for skin disease research; successfully lobbying the FDA for the approval of methotrexate for the treatment of severe psoriasis; and opening the world’s first support center providing free personalized assistance for people with psoriatic disease. Recently, members of the NPF Medical Board issued the first US paper1 that outlines psoriasis treatment targets and goals for individuals and health care providers to work on together to achieve clear skin and reduce disease burden.
The theme of the NPF 50th Year Celebration is “Driving Discovery, Creating Community.” The Foundation will celebrate the achievements of the past 50 years and recognize the individuals and milestones that have made significant contributions to the psoriatic disease community. In addition, the Foundation has planned a yearlong schedule of events to commemorate the anniversary, starting with a formal celebration on June 8, 2017 at the Plaza Hotel in New York City, and followed by the National Volunteer Conference and Research Symposium August 4-6, 2017 in Chicago, IL. Various TeamNPF events will also be held across the country.
Reference
1. Armstrong AW, Siegel MP, Bagel J, et al. From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis. J Am Acad Dermatol. 2017;76(2):290-298.
This year the National Psoriasis Foundation (NPF) celebrates 50 years of patient support, advocacy, research funding, education, and outreach to the more than 8 million individuals living with psoriasis and psoriatic arthritis. Originally formed in 1966 as The Psoriasis Society of Oregon, and officially becoming the National Psoriasis Foundation in 1967, its mission is focused on driving efforts to cure psoriatic disease and dramatically improving the lives of those affected.
“NPF has been a pioneer in supporting research efforts that have led to the groundbreaking treatments used today,” said Randy Beranek, NPF president and chief executive officer. “During our 50th year, we are excited to recognize the people and milestones that have contributed so much to the psoriatic disease community, and remain committed to supporting research efforts towards finding a cure and dramatically improving the health outcomes of all affected by psoriasis and psoriatic arthritis.”
Throughout its first 50 years, NPF has made significant contributions in advancing the research of treatments that have helped millions of people. NPF has supported innovative approaches to treating psoriasis and psoriatic arthritis, including topical medications and the biologic treatments that exist today. To date, NPF has funded more than $15 million in research grants and fellowships. To commemorate the 50th anniversary, NPF plans to raise an additional $2 million for early scientific career research programs in 2017.
Much work still needs to be done to improve access to treatments and to find a cure, according the NPF. “We have only scratched the surface of what could be possible in treating—and ultimately curing—psoriasis and psoriatic arthritis. Advancements in psoriatic disease research are happening all the time, and NPF remains committed to funding this research while offering programs and services that support even more patients,” said Colby Evans, MD, NPF board chair.
NPF milestones achievements include securing for line-item funding in a federal budget for skin disease research; successfully lobbying the FDA for the approval of methotrexate for the treatment of severe psoriasis; and opening the world’s first support center providing free personalized assistance for people with psoriatic disease. Recently, members of the NPF Medical Board issued the first US paper1 that outlines psoriasis treatment targets and goals for individuals and health care providers to work on together to achieve clear skin and reduce disease burden.
The theme of the NPF 50th Year Celebration is “Driving Discovery, Creating Community.” The Foundation will celebrate the achievements of the past 50 years and recognize the individuals and milestones that have made significant contributions to the psoriatic disease community. In addition, the Foundation has planned a yearlong schedule of events to commemorate the anniversary, starting with a formal celebration on June 8, 2017 at the Plaza Hotel in New York City, and followed by the National Volunteer Conference and Research Symposium August 4-6, 2017 in Chicago, IL. Various TeamNPF events will also be held across the country.
Reference
1. Armstrong AW, Siegel MP, Bagel J, et al. From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis. J Am Acad Dermatol. 2017;76(2):290-298.
This year the National Psoriasis Foundation (NPF) celebrates 50 years of patient support, advocacy, research funding, education, and outreach to the more than 8 million individuals living with psoriasis and psoriatic arthritis. Originally formed in 1966 as The Psoriasis Society of Oregon, and officially becoming the National Psoriasis Foundation in 1967, its mission is focused on driving efforts to cure psoriatic disease and dramatically improving the lives of those affected.
“NPF has been a pioneer in supporting research efforts that have led to the groundbreaking treatments used today,” said Randy Beranek, NPF president and chief executive officer. “During our 50th year, we are excited to recognize the people and milestones that have contributed so much to the psoriatic disease community, and remain committed to supporting research efforts towards finding a cure and dramatically improving the health outcomes of all affected by psoriasis and psoriatic arthritis.”
Throughout its first 50 years, NPF has made significant contributions in advancing the research of treatments that have helped millions of people. NPF has supported innovative approaches to treating psoriasis and psoriatic arthritis, including topical medications and the biologic treatments that exist today. To date, NPF has funded more than $15 million in research grants and fellowships. To commemorate the 50th anniversary, NPF plans to raise an additional $2 million for early scientific career research programs in 2017.
Much work still needs to be done to improve access to treatments and to find a cure, according the NPF. “We have only scratched the surface of what could be possible in treating—and ultimately curing—psoriasis and psoriatic arthritis. Advancements in psoriatic disease research are happening all the time, and NPF remains committed to funding this research while offering programs and services that support even more patients,” said Colby Evans, MD, NPF board chair.
NPF milestones achievements include securing for line-item funding in a federal budget for skin disease research; successfully lobbying the FDA for the approval of methotrexate for the treatment of severe psoriasis; and opening the world’s first support center providing free personalized assistance for people with psoriatic disease. Recently, members of the NPF Medical Board issued the first US paper1 that outlines psoriasis treatment targets and goals for individuals and health care providers to work on together to achieve clear skin and reduce disease burden.
The theme of the NPF 50th Year Celebration is “Driving Discovery, Creating Community.” The Foundation will celebrate the achievements of the past 50 years and recognize the individuals and milestones that have made significant contributions to the psoriatic disease community. In addition, the Foundation has planned a yearlong schedule of events to commemorate the anniversary, starting with a formal celebration on June 8, 2017 at the Plaza Hotel in New York City, and followed by the National Volunteer Conference and Research Symposium August 4-6, 2017 in Chicago, IL. Various TeamNPF events will also be held across the country.
Reference
1. Armstrong AW, Siegel MP, Bagel J, et al. From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis. J Am Acad Dermatol. 2017;76(2):290-298.
